In a small trial, three patients with CML received three series of four administrations of BCR-ABL peptide-pulsed DCs, and all patients developed peptide-specific cellular immune responses with no clinical response. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.